Neuropathic pain syndrome is a challenge to treat and, even with appropriate evidence-based treatment, only a 40% reduction of symptoms can be achieved in approximately half of patients.

Finnerup NB, Kuner R, Jensen TS: Neuropathic pain: from mechanisms to treatment. Physiol Rev 2021; 101: 259–301 CrossRef MEDLINE 9. Gangadharan V, Zheng H, Taberner FJ, et al.: Neuropathic pain ...

Although evidence exists suggesting that some diseases causing neuropathic pain respond differently to the same medications, [85] we can conclude that it seems inevitable to base a treatment ...

A Manitoba woman is suing St. Boniface Hospital and two staff after undergoing a medical procedure that she says left her ...

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with ...

For people suffering from chronic knee pain, especially those over 50, a new treatment is offering hope and relief.

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system ...

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

Nalu Medical, Inc. (“Nalu”), a leader in peripheral nerve stimulation, announced the publication of a study in Pain Management journal showing that the use of Nalu PNS therapy in chronic pain patients ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance ...